Wnt signaling in cancer DOI Creative Commons
Tianzuo Zhan, Niklas Rindtorff, Michael Boutros

et al.

Oncogene, Journal Year: 2016, Volume and Issue: 36(11), P. 1461 - 1473

Published: Sept. 12, 2016

Wnt signaling is one of the key cascades regulating development and stemness, has also been tightly associated with cancer. The role in carcinogenesis most prominently described for colorectal cancer, but aberrant observed many more cancer entities. Here, we review current insights into novel components pathways describe their impact on development. Furthermore, highlight expanding functions both solid liquid tumors. We findings how affects maintenance stem cells, metastasis immune control. Finally, provide an overview strategies to antagonize challenges that are such approaches.

Language: Английский

Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade DOI Open Access
Dung T. Le, Jennifer N. Durham, Kellie N. Smith

et al.

Science, Journal Year: 2017, Volume and Issue: 357(6349), P. 409 - 413

Published: July 27, 2017

The genomes of cancers deficient in mismatch repair contain exceptionally high numbers somatic mutations. In a proof-of-concept study, we previously showed that colorectal with deficiency were sensitive to immune checkpoint blockade antibodies programmed death receptor-1 (PD-1). We have now expanded this study evaluate the efficacy PD-1 patients advanced repair-deficient across 12 different tumor types. Objective radiographic responses observed 53% patients, and complete achieved 21% patients. Responses durable, median progression-free survival overall still not reached. Functional analysis responding patient demonstrated rapid vivo expansion neoantigen-specific T cell clones reactive mutant neopeptides found tumor. These data support hypothesis large proportion neoantigens make them blockade, regardless cancers' tissue origin.

Language: Английский

Citations

5746

Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer DOI Open Access
Edward B. Garon, Naiyer A. Rizvi, Rina Hui

et al.

New England Journal of Medicine, Journal Year: 2015, Volume and Issue: 372(21), P. 2018 - 2028

Published: April 19, 2015

We assessed the efficacy and safety of programmed cell death 1 (PD-1) inhibition with pembrolizumab in patients advanced non–small-cell lung cancer enrolled a phase study. also sought to define validate an expression level PD-1 ligand (PD-L1) that is associated likelihood clinical benefit.

Language: Английский

Citations

5658

Elements of cancer immunity and the cancer–immune set point DOI
Daniel S. Chen, Ira Mellman

Nature, Journal Year: 2017, Volume and Issue: 541(7637), P. 321 - 330

Published: Jan. 1, 2017

Language: Английский

Citations

4339

The consensus molecular subtypes of colorectal cancer DOI
Justin Guinney, Rodrigo Dienstmann, Xin Wang

et al.

Nature Medicine, Journal Year: 2015, Volume and Issue: 21(11), P. 1350 - 1356

Published: Oct. 12, 2015

Language: Английский

Citations

4308

Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response DOI
Peng Jiang, Shengqing Gu, Deng Pan

et al.

Nature Medicine, Journal Year: 2018, Volume and Issue: 24(10), P. 1550 - 1558

Published: Aug. 13, 2018

Language: Английский

Citations

3923

The biology and management of non-small cell lung cancer DOI
Roy S. Herbst, Daniel Morgensztern,

Chris Boshoff

et al.

Nature, Journal Year: 2018, Volume and Issue: 553(7689), P. 446 - 454

Published: Jan. 1, 2018

Language: Английский

Citations

3825

Colorectal cancer DOI
Evelien Dekker, Pieter J. Tanis,

Jasper L.A. Vleugels

et al.

The Lancet, Journal Year: 2019, Volume and Issue: 394(10207), P. 1467 - 1480

Published: Oct. 1, 2019

Language: Английский

Citations

3742

Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial DOI
Jonathan E. Rosenberg, Jean H. Hoffman-Censits,

Tom Powles

et al.

The Lancet, Journal Year: 2016, Volume and Issue: 387(10031), P. 1909 - 1920

Published: March 5, 2016

Language: Английский

Citations

3416

Tumor mutational load predicts survival after immunotherapy across multiple cancer types DOI
Robert M. Samstein, Chung‐Han Lee, Alexander N. Shoushtari

et al.

Nature Genetics, Journal Year: 2019, Volume and Issue: 51(2), P. 202 - 206

Published: Jan. 8, 2019

Language: Английский

Citations

3356

ESMO consensus guidelines for the management of patients with metastatic colorectal cancer DOI Creative Commons
Eric Van Cutsem, Andrés Cervantes, René Adam

et al.

Annals of Oncology, Journal Year: 2016, Volume and Issue: 27(8), P. 1386 - 1422

Published: July 6, 2016

Language: Английский

Citations

3020